Form 4: Director Kathleen Tregoning Receives CMPS Stock Options

Compass Pathways director Kathleen Tregoning was granted 41,119 stock options as part of a standard equity compensation package.

Summary

• Director Kathleen Tregoning received a grant of 41,119 share options on May 27, 2026.
• The options have an exercise price of $11.85 per share.
• The options are set to expire on May 26, 2036.
• Vesting occurs in 36 equal monthly installments starting June 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $11.85 exercise price.

Future Outlook

The options vest over a three-year period, indicating a long-term retention and performance incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to ensure board alignment with corporate milestones and long-term growth objectives.

Comparison to Industry Standards

• The three-year monthly vesting schedule is consistent with standard corporate governance practices for board members in the life sciences industry.
• The use of stock options as a primary component of director compensation is common among mid-cap biotech firms to preserve cash.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon future exercise of options.

Next Steps

• Vesting of the first tranche of options on June 27, 2026.

Key Dates

Keywords

COMPASS Pathways, CMPS, Director Compensation, Stock Options, Insider Transaction, SEC Form 4